AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for CD19 Positive

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL NCT07244406Phase 21 site๐Ÿ“ Beijing Hebei Senlang Biotechnology Inc., Ltd. ยท Tests: S1904 CD19 CAR-T A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Chongqing Chongqing Precision Biotech Co., Ltd ยท Tests: pCAR-19B cells CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site๐Ÿ“ Riyadh King Faisal Specialist Hospital & Research Center ยท Tests: CAR T cells chimeric antigen receptor cells Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies NCT07284927Phase 11 site๐Ÿ“ Suzhou PersonGen BioTherapeutics (Suzhou) Co., Ltd. ยท Tests: LV009 Injection A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Aurora Autolus Limited ยท Tests: AUTO1 Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies NCT07584889Phase 1, Phase 21 site๐Ÿ“ Shenzhen Shenzhen University General Hospital ยท Tests: CAR-T cell CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. NCT06752785Phase 11 site๐Ÿ“ Guangzhou Guangzhou Women and Children's Medical Center ยท Tests: CAR-T Therapy CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT NCT07441291Phase 31 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CAR-T, DLI Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA NCT07620275Phase 13 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Tianjin Chinese PLA General Hospital ยท Tests: KSVCBD injection Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma NCT06180174Phase 11 site๐Ÿ“ Beijing Chongqing Precision Biotech Co., Ltd ยท Tests: MC-1-50 Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Tรผbingen๐Ÿ“ Ulm University Hospital Tuebingen ยท Tests: Tafasitamab CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+ NCT06355739NA2 sites๐Ÿ“ Tianjin๐Ÿ“ Tianjin Zhu Xiaofan ยท Tests: CAR T cell injection Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Denver Vironexis Biotherapeutics Inc. ยท Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) NCT07222579Phase 21 site๐Ÿ“ Morgantown West Virginia University ยท Tests: Subcutaneous Blinatumomab Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia NCT07429461EARLY Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: SYNCAR-100 Injection A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors NCT07131254EARLY Phase 11 site๐Ÿ“ Ganzhou Grit Biotechnology ยท Tests: GT719 Injection A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia NCT07205315EARLY Phase 12 sites๐Ÿ“ Zhengzhou๐Ÿ“ Tianjin Grit Biotechnology ยท Tests: GT801 Injection Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia NCT04881240Phase 11 site๐Ÿ“ Memphis St. Jude Children's Research Hospital ยท Tests: CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine, Mesna, CliniMACS Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA NCT07620314Phase 11 site๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: KSVCBD injection CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia NCT06847269Phase 21 site๐Ÿ“ Memphis St. Jude Children's Research Hospital ยท Tests: Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients NCT04440436Phase 1, Phase 21 site๐Ÿ“ Beijing Beijing Immunochina Medical Science & Technology Co., Ltd. ยท Tests: IM19 CAR-T Cells Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation NCT06247501Phase 21 site๐Ÿ“ Seoul Seoul National University Hospital ยท Tests: SNUH-CD19-CAR-T Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018Phase 11 site๐Ÿ“ Tianjin CytoCares Inc ยท Tests: CC312 Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia NCT04684147Phase 211 sites๐Ÿ“ Beijing๐Ÿ“ Chongqing๐Ÿ“ Guangzhou Juventas Cell Therapy Ltd. ยท Tests: single dose of CNCT19 Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD19/CD22-CAR T cells CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies NCT03765177Phase 1, Phase 23 sites๐Ÿ“ Vancouver๐Ÿ“ Winnipeg๐Ÿ“ Ottawa Ottawa Hospital Research Institute ยท Tests: CLIC-1901 Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies NCT07312630EARLY Phase 11 site๐Ÿ“ Hefei PersonGen BioTherapeutics (Suzhou) Co., Ltd. ยท Tests: LV009 Injection Infusion Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL NCT07271121Phase 21 site๐Ÿ“ Amman King Hussein Cancer Center ยท Tests: MB-CART-19.1 CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL NCT06179524Phase 21 site๐Ÿ“ Tianjin Beijing Yongtai Ruike Biotechnology Company Ltd ยท Tests: CAR-T-19 cell injection A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL NCT06220487Phase 21 site๐Ÿ“ Guangzhou Nanfang Hospital, Southern Medical University ยท Tests: Prednisone, Olverembatinib, Blinatumomab, Chidamide
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy